We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HEN:XETRHenkel AG & Co. KGaA Analysis

Data as of 2026-06-13 - not real-time

€510.60

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

LVMH’s price is comfortably above its short‑term moving averages yet still under the long‑term average, placing the stock in a neutral technical zone. The RSI is well above the midpoint, indicating continued buying pressure, while the MACD line sits above its signal, confirming bullish momentum. Strong gross and operating margins together with a solid return on equity underscore the company’s underlying profitability, even as revenue has slipped modestly year‑over‑year. The recent announcement of a 1,000‑1,200‑person restructuring and the divestiture of the Marc Jacobs brand signal a focused cost‑control strategy, while the approved dividend of €13 per share demonstrates a commitment to shareholder returns.
Analyst consensus remains positive with a “buy” rating and price targets suggesting upside, though a discounted cash‑flow model points to a valuation gap that warrants caution. Investors should weigh the brand’s resilience and cash‑flow generation against the modest revenue decline, elevated debt levels, and a high short‑term volatility environment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical positioning near short‑term averages
  • Pending impact of announced workforce reductions
  • Stable dividend payout supporting income investors

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic divestiture improving focus on core luxury segments
  • Analyst price targets indicating upside potential
  • Strong cash‑flow generation to service debt and fund growth

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • World‑class brand portfolio with resilient demand
  • Consistently high margins and solid ROE
  • Commitment to dividend and share buy‑backs enhancing total return

Key Metrics & Analysis

Financial Health

Revenue Growth-4.70%
Profit Margin13.46%
P/E Ratio23.4
ROE16.24%
ROA7.58%
Debt/Equity53.34
P/B Ratio3.8
Op. Cash Flow€18.9B
Free Cash Flow€11.7B

Technical Analysis

TrendNeutral
RSI66.5
Support€444.35
Resistance€521.20
MA 20€477.41
MA 50€473.33
MA 200€542.52
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value€266.25
Target Price€584.89
Upside/Downside14.55%
GradeFair
TypeBlend
Dividend Yield2.64%

Risk Assessment

Beta0.04
Volatility31.59%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.